A. Abbasszade
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
A. Abbasszade has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
A. Mokhtariardekani
Endocrinology and Metabolism Research Center, Institute of Basic and Clinical Physiology Science, & Physiology Research Center, Kerman University of Medical Sciences, Kerman, Iran
1 shared publication- Ali Emadzadeh
Department of Internal Medicine, MMS.C., Islamic Azad University, Mashhad, Iran
1 shared publication - Houshang Sanadgol
Department of Nephrology, Hasheminejad Kidney Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
1 shared publication - Mehrdad SalekShahabi
Department of Medicine, TaMS.C. Islamic Azad University Tabriz Iran
1 shared publication - Shiva Hosseinian
Iran University of Medical Sciences
1 shared publication - Sina Salem Ahim
General Medicine, Fasa University of Medical Sciences, Fasa, Iran
1 shared publication
Latest Publications
- 28 February 2026
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
Renal manifestations and implications in polycystic ovary syndrome; an analytical review
Insulin resistance in polycystic ovary syndrome (PCOS) contributes to renal dysfunction through multiple interconnected mechanisms. In PCOS, insulin resistance leads to compensatory hyperinsulinemia, which exacerbates metabolic disturbances including hyperandrogenism and systemic inflammation. These factors collectively promote renal injury. Meanwhile, insulin resistance in PCOS promotes hypertension and endothelial dysfunction, which impair renal microcirculation. Hyperinsulinemia increases sodium retention and activates the renin-angiotensin-aldosterone system (RAAS), further elevating blood pressure and causing glomerular hyperfiltration and damage. Insulin resistance also contributes to dyslipidemia and oxidative stress, accelerating atherosclerosis and renal vascular injury. Moreover, insulin resistance worsens hyperuricemia by reducing renal uric acid excretion, which is a direct nephrotoxic factor. Persistent hyperuricemia leads to inflammation and fibrosis within the kidneys, potentially progressing to chronic kidney disease (CKD). In addition, systemic low-grade inflammation and oxidative stress driven by insulin resistance and PCOS-related hyperandrogenism also induce renal tissue injury through inflammatory cytokines and apoptotic pathways, contributing to impairment in renal function.
- 28 February 2026
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
Renal manifestations and implications in polycystic ovary syndrome; an analytical review
Insulin resistance in polycystic ovary syndrome (PCOS) contributes to renal dysfunction through multiple interconnected mechanisms. In PCOS, insulin resistance leads to compensatory hyperinsulinemia, which exacerbates metabolic disturbances including hyperandrogenism and systemic inflammation. These factors collectively promote renal injury. Meanwhile, insulin resistance in PCOS promotes hypertension and endothelial dysfunction, which impair renal microcirculation. Hyperinsulinemia increases sodium retention and activates the renin-angiotensin-aldosterone system (RAAS), further elevating blood pressure and causing glomerular hyperfiltration and damage. Insulin resistance also contributes to dyslipidemia and oxidative stress, accelerating atherosclerosis and renal vascular injury. Moreover, insulin resistance worsens hyperuricemia by reducing renal uric acid excretion, which is a direct nephrotoxic factor. Persistent hyperuricemia leads to inflammation and fibrosis within the kidneys, potentially progressing to chronic kidney disease (CKD). In addition, systemic low-grade inflammation and oxidative stress driven by insulin resistance and PCOS-related hyperandrogenism also induce renal tissue injury through inflammatory cytokines and apoptotic pathways, contributing to impairment in renal function.